Podcasts about erythropoietin

Dr Glenn McConell chats with Associate Professor from the University of Wisconsin-Madison, USA. Jill is an expert on the brain and exercise. We discussed the effect of acute (one bout) and chronic physical activity/ exercise on cognitive function, brain blood flow (BBF), dementia/Alzheimer's disease risk and progression etc. A very interesting chat. Twitter: @Barnes_Lab0:00. Introduction and welcome2:01. How Jill got into exercise research4:25. Studying with Hiro O. Tanaka6:00. Researching with Michael Joyner7:45. How measure brain blood flow (BBF)10:00. Blood vessels that supply the brain and blood flow19:16. What would look at if had unlimited funding?20:32. BBF vs glucose use in the brain21:30. Regional blood flow in the brain22:40. Does BBF increase during exercise?24:40. Blood pressure and regulation of brain blood flow29:00. Effect of exercise intensity in BBF32:25. Hypnosis/anticipatory rises in BBF34:30. BBF distribution has not been examined much during exercise37:00. Cognitive tests and BBF38:00. Why does BBF decrease during very intense exercise?41:00. Central fatigue and BBF42:30. Exercise training and BBF45:00. BBF and cognitive function46:20. How quickly does BBF increase with exercise?47:25. Fitness and BBF at rest49:55. Cognition and exercise/lifestyle51:44. Exercjse intensity and the brain53:10. Resistance training and cognitive function55:07. Exercise and brain endothelial function57:10. Exercise and the risk of stroke59:35. Exercise and the risk of dementia/Alzheimers disease1:02:14. Exercise and mental health1:03:45. Diet and BBF/brain health1:06:15. Sex differences in BBF1:12:57. Age and BBF1:15:20. Fitness/strength and cognition etc1:16:10. Erythropoietin, hemoglobin and cognitive function.1:18:48. Exercise and myokines, BDNF, exosomes1:21:10. Neurogenesis and exercise1:22:20. Exercise, cognition and hypertension/diabetes1:25:00. Prevention of Alzheimer's disease/dementia1:27:00. Exercise intensity and mode of exercise1:29:55. BBF during resistance exercise1:31:20. Controversies in the field1:34:52. Keep things simple re exercise1:37:00. Takeaway messages1:39:57. Outro Inside Exercise brings to you the who's who of research in exercise metabolism, exercise physiology and exercise's effects on health. With scientific rigor, these researchers discuss popular exercise topics while providing practical strategies for all.The interviewer, Emeritus Professor Glenn McConell, has an international research profile following 30 years of Exercise Metabolism research experience while at The University of Melbourne, Ball State University, Monash University, the University of Copenhagen and Victoria University.He has published over 120 peer reviewed journal articles and recently edited an Exercise Metabolism eBook written by world experts on 17 different topics (https://link.springer.com/book/10.1007/978-3-030-94305-9).Connect with Inside Exercise and Glenn McConell at:Twitter: @Inside_exercise and @GlennMcConell1Instagram: insideexerciseFacebook: Glenn McConellLinkedIn: Glenn McConell https://www.linkedin.com/in/glenn-mcconell-83475460ResearchGate: Glenn McConellEmail: glenn.mcconell@gmail.comSubscribe to Inside exercise:Spotify: shorturl.at/tyGHLApple Podcasts: shorturl.at/oFQRUYouTube: https://www.youtube.com/@insideexerciseAnchor: https://anchor.fm/insideexerciseGoogle Podcasts: shorturl.at/bfhHIAnchor: https://anchor.fm/insideexercisePodcast Addict: https://podcastaddict.com/podcast/4025218Not medical advice

Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos; nuestras futuras doctoras Valentina Giraldo y Laura Molina y su anfitriona Maria Flores Cordova, médico residente de pediatría. No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comLos artículos que se tratan en el episodio de hoy están listados aquí: Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.Hundscheid T, Onland W, Kooi EMW, Vijlbrief DC, de Vries WB, Dijkman KP, van Kaam AH, Villamor E, Kroon AA, Visser R, Mulder-de Tollenaer SM, De Bisschop B, Dijk PH, Avino D, Hocq C, Zecic A, Meeus M, de Baat T, Derriks F, Henriksen TB, Kyng KJ, Donders R, Nuytemans DHGM, Van Overmeire B, Mulder AL, de Boode WP; BeNeDuctus Trial Investigators.N Engl J Med. 2023 Mar 16;388(11):980-990. doi: 10.1056/NEJMoa2207418. Epub 2022 Dec 6.Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group.N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.Antenatal dexamethasone for late preterm birth: A multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial.WHO ACTION Trials Collaborators.EClinicalMedicine. 2022 Feb 12;44:101285. doi: 10.1016/j.eclinm.2022.101285. eCollection 2022 Feb.Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.Wu YW, Comstock BA, Gonzalez FF, Mayock DE, Goodman AM, Maitre NL, Chang T, Van Meurs KP, Lampland AL, Bendel-Stenzel E, Mathur AM, Wu TW, Riley D, Mietzsch U, Chalak L, Flibotte J, Weitkamp JH, Ahmad KA, Yanowitz TD, Baserga M, Poindexter BB, Rogers EE, Lowe JR, Kuban KCK, O'Shea TM, Wisnowski JL, McKinstry RC, Bluml S, Bonifacio S, Benninger KL, Rao R, Smyser CD, Sokol GM, Merhar S, Schreiber MD, Glass HC, Heagerty PJ, Juul SE; HEAL Consortium.N Engl J Med. 2022 Jul 14;387(2):148-159. doi: 10.1056/NEJMoa2119660. Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal. Soy tu host, Maria Flores Cordova, MD. Presentado por los Neonatólogos Elena Itriago MD, Dani de Luis Rosell MD, Carolina Michel MD, las futuras doctoras Marla Fortoul, Valentina Giraldo, Laura Molina. Creado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠Erythropoietin from the Heme section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Welcome to Episode #385 of the 303 Endurance Podcast. We're your hosts Coach Rich Soares and 303 Chief Editor, Bill Plock. Thanks for joining us for another week of endurance news, coaching tips and discussion.   From the great state of TX we have the IMTX pro race and USAT Multisport Fest last weekend. Next weekend is the PTO Euro Open and 70.3 Champs in St. George next weekend. Plus owning up to an EPO violation by Colin Chartier and World Champion Tips at the TriDot Kona 2023 Kickoff Event last night.   Show Sponsor: UCAN Generation UCAN has a full line of nutrition products powered by LIVESTEADY to fuel your sport.   LIVSTEADY was purposefully designed to work with your body, delivering long-lasting energy you can feel. LIVSTEADY's unique time-release profile allows your body to access energy consistently throughout the day, unlocking your natural ability to stay focused and calm while providing the fuel you need to meet your daily challenges.   Use UCAN in your training and racing to fuel the healthy way, finish stronger and recover more quickly!  Use the code 303UCAN for 20% off at ucan.co/discount/303UCAN/ or ucan.co   In Today's Show Endurance News - IMTX, EPO, 70.3 NA Champs in St. George What's new in the 303 - Kona 2023 Tips from Mark Allen, Miranda Carfrae and Michellie Jones Ask a Coach - Question (and Response) of the Week Video of the Week - USAT Multisport Festival Draft Legal and Netflix TDF Unchained Trailer   Endurance News: IRONMAN Texas 2023 men's results: Rudy von Berg wins a thriller By Jonathan Turner   America's Rudy von Berg claimed a thrilling win over Poland's Robert Wilkowiecki and IRONMAN debutant Matthew Marquardt (USA) as the three of them finished within 22 seconds after nearly eight hours of racing at Memorial Hermann IRONMAN Texas – The Americas Championship.   Last year saw a sprint finish between Ben Hoffman and Magnus Ditlev and the drama matched it 12 months on.   Von Berg and Wilkowiecki had swapped the lead on the marathon but behind them Marquardt was demonstrating why he's a rookie to keep a very close eye on.   The overall age-group winner at Kona last year after only starting the sport in 2021, this was his first ever IRONMAN race as a pro and he closed dramatically late on as Wilkowiecki looked set for the win.   But von Berg was always within range and he pounced just as the Pole started to struggle inside the final mile.   There was drama of an unwanted kind for the two big pre-race favourites – three-time Texas winner Matt Hanson's chances disappeared after an age-grouper apparently crashed in front of him while Joe Skipper was reported to have taken on a wrong turn on the bike to scupper his hopes.   And it wasn't a big surprise to see last year's #1-ranked swimmer Andrew Horsfall-Turner (GBR) set the pace in the water.   But he didn't have things all his own way – he headed a group of four at the halfway point, with Wilkowiecki on his feet, closely followed by von Berg and Marquardt.   And that was how it stayed heading into T1 as Horsfall-Turner clocked 48:50, with Marquardt rounding out the leaders as he underlined his swim prowess.   That quartet had over two minutes and more on the rest.   Of the big favourites, Hanson was 10th out of the water at +3:38. And Skipper followed his pre-race promise of “a decent swim and sitting on the best feet I can” as he too was in that same pack.   Heading onto the bike, von Berg lost a bit of time in T1 which left a leading trio out in front as the likes of Skipper and Hanson set about trying to hunt them down. All eyes were on Skipper early on the bike and the promised ‘new Dad watts‘ looked to be forthcoming as he started to cut through the field.   His deficit on the leaders was down to 2:10 at 40 miles but the dynamic of the race started to change after that.   For the leading four of von Berg, Wilkowiecki, Marquardt and Horsfall-Turner were working well together and they gradually started to put time between themselves and the rest. Unfortunately an age-group athlete apparently crashed in front of Hanson on the looped bike course and left him with nowhere to go and out of contention.   So heading into T2 it was von Berg and Wilkowiecki who had moved clear, with each of them clocking best-of-the-day 4:05 bike splits.   It was just the fourth IRONMAN of von Berg's career and his performance was a nod to coach Mikal Iden, with whom he's worked since the latter part of 2022.   Speaking in the build up, von Berg had said his goal here was “the podium or better” and that was very much on the cards.   Wilkowiecki was the only one who could match him and starting the run there were just 23 seconds between them.   Marquardt was at +2:48, Horsfall-Turner +5:42 and Guilloux +7:02 while Skipper dropped right down the standings in the last few miles of the bike section, with the live broadcast reporting he'd taken a wrong turn – all of which meant he began the marathon over 20 minutes back on the leaders.   It was fascinating up front as von Berg and Wilkowiecki swapped the lead early on.   Both looked strong but Marquardt was charging in the second half and taking chunks of time back on both of them.   No fewer than five IRONMAN World Championship slots in Nice were up for grabs and the trio were miles clear of their rivals and guaranteed a place barring a huge mishap.   It was Wilkowiecki who appeared to be holding strongest but he suddenly started to send out distress signals going into the final mile and von Berg had timed his challenge perfectly. Just 12 seconds separated them on the line and Marquardt was only 21 seconds adrift on a phenomenal pro debut.   It was nearly 10 minutes back to Guilloux in fourth, with Cody Beals taking the final Nice slot in fifth.   PRO Men 1. Rudy von Berg (USA) – 7:44:51 2. Robert Wilkowiecki (POL) – 7:45:04 3. Matthew Marquardt (USA) – 7:45:12 4. Arnaud Guilloux (FRA) – 7:54:21 5. Cody Beals (CAN) – 7:57:18 6. Ivan Tutukin (KAZ) – 8:01:40 7. David Plese (SLO) – 8:03:58 8. Thomas Davis (GBR) – 8:05:33 9. Adam Feigh (USA) – 8:06:04 10. Michael Weiss (AUT) – 8:06:12     American Pro Triathlete Collin Chartier Admits EPO Use After Positive Drug Test An out-of-competition test by Ironman in February of this year detected the presence of erythropoietin (EPO) in a sample collected from 2022 U.S. Open Triathlon winner Collin Chartier. APRIL 24, 2023 CHRIS FOSTER, TIM HEMING    Heading out the door? Read this article on the new Outside+ app available now on iOS devices for members! Download the app.   The International Testing Agency (ITA) announced this morning that American pro triathlete Collin Chartier tested positive for EPO from an out-of-competition test performed on February 10, 2023. Upon receipt of the positive test, Chartier admitted to the use of the banned substance to the agency, and as a result received a reduced ban of three years, down from four according to the ITA.   Erythropoietin, known as EPO, is prohibited under World Anti-Doping Agency regulations because it stimulates erythropoiesis (red blood cell production) and can modify the body's capacity to transport oxygen, increasing stamina, and performance.   In a social media post released on Monday morning, Chartier went on to further admit his use of a “PED in November after feeling like I have lost my way in the sport,” due to “intense pressure and expectations to win the biggest races in 2024.” His post went on to say that he had no plans to return to the sport after the three-year ban was lifted.   Despite having a relatively inauspicious short course career, Chartier was an up-and-coming triathlete in the long-course scene.   Coached by Mikal Iden, the brother of reigning Ironman world champion Gustav, he was a shock winner of last year's inaugural PTO U.S. Open in Dallas in September where he won $100,000 topping a highly competitive field including Magnus Ditlev and Sam Long.   Training alongside two-time Ironman world championship runner-up Lionel Sanders, the victory came three weeks after his first full-distance Ironman victory in Mont-Tremblant. Chartier then had a disappointing debut in Hawaii in the Ironman World Championship in October when he finished 35th.   Prior to those results, Chartier's highest competitive finish was a win at Challenge Salou in October 2021 and a third-place finish at 70.3 Boulder in August of the same year.   Fellow pros posting in response to Chartier's Instagram message gave mixed comments, with 2014 Ironman world champion Sebastian Kienle saying: “Let me guess, you bought it on the internet and also learned how to use it – all from the internet. Nobody helped you, nobody knew.”   Former triathlete-turned-elite-runner Lauren Goss commented: “Dude brave of you . No one sees the mental health side. Walk through the fire.”   Despite being PTO-ranked No 14 and an automatic qualifier, Chartier was not on the start-list for May's big money PTO European Open in Ibiza. He had originally planned to race Saturday's Ironman Texas and had been training at altitude in California, Ecuador, and Girona in Spain.   The International Testing Agency (ITA), the testing body who administered and discovered the adverse finding is a Switzerland-based, not-for-profit that claims no connection to “sporting or political powers” on its website. The ITA conducts testing for the Ironman organization from a pool of 46 professional athletes currently registered in the Ironman Registered Testing Pool (RTP) as of this writing—which includes Chartier.   Coincidentally, Ironman said that 2023 is the first year the brand has delegated results management and prosecution of doping cases to the ITA. “Testing plans are based on a variety of factors and differ from individual athlete to individual athlete, with review of specific performances, intelligence, and the testing plans of National Anti-Doping agencies to maximize resources,” Ironman said in a statement.   “Ironman does acknowledge the significance of the decision made by Collin in promptly accepting responsibility for his actions.”   What's New in the 303:   Team Kona 2023 TriDot Women's Team Mark - give your competitor the food that doesn't have nutrition; no racing 6 weeks from kona; start at 300 calories per hour Michellie - Climatize but don't spend a season in sun, humidity and heat. Make sure you know your sweat rate and sodium content. If your afraid of an ocean swim, come up with a mantra Rinnie - be honest about yourself and your body. Don't just plow through a session. If you have a stressful day, take a day off. Stay at the King K the night before the race. The athlete that trains their body to take on the volume of calories you need. 1.5g/ KG/hr Siri - Don't beat the dead horse. 42 participants including Matt Bach - commented on hydration and then said any other coaches want to chime in.   Video of the Week: 2023 Multisport National Championships Festival – Draft-Legal Sprint Duathlon & Triathlon Tour de France : Unchained | Official teaser | Netflix    

A series of extraordinary events has threatened to bring down athletics champ Peter Bol. Can his reputation ever recover? Find out more about The Front podcast here and read about this story and more on The Australian's website or search for The Australian in your app store. This episode of The Front is presented and produced by Kristen Amiet, and edited by Tiffany Dimmack. Our regular host is Claire Harvey. The multimedia editor is Lia Tsamoglou, and original music composed by Jasper Leak.See omnystudio.com/listener for privacy information.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.04.527116v1?rss=1 Authors: Singh, M., Zhao, Y., Daguano Gastaldi, V., Wojcik, S. M., Curto, Y., Kawaguchi, R., Merino, R. M., Fernandez Garcia-Agudo, L., Taschenberger, H., Brose, N., Geschwind, D., Nave, K.-A., Ehrenreich, H. Abstract: Recombinant human erythropoietin (rhEPO) has potent procognitive effects,hematopoiesis-independent, but underlying mechanisms and physiological role of brain-expressed EPO have remained obscure. Here, we provide encyclopedic transcriptional hippocampal profiling of mice treated with rhEPO. Based on ~108,000 single nuclei, we unmask multiple pyramidal lineages with their comprehensive molecular signatures. By temporal profiling and gene regulatory analysis, we build a developmental trajectory of CA1 pyramidal neurons derived from multiple predecessor lineages and elucidate gene regulatory networks underlying their fate determination. With EPO as tool, we discover novel populations of newly differentiating pyramidal neurons, overpopulating to ~200% upon rhEPO with upregulation of genes crucial for neurodifferentiation, dendrite growth, synaptogenesis, memory formation, and cognition. Using a Cre-based approach to visually distinguish pre-existing from newly formed pyramidal neurons for patch-clamp recordings, we learn that rhEPO treatment differentially affects excitatory and inhibitory inputs. Our findings provide mechanistic insight into how EPO modulates neuronal functions and networks Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In this episode, we review the high-yield topic of Erythropoietin from the Hematology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/navigating-ckd-podcast#group-tabs-node-course-default1To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs. However, HIF-PHIs place in therapy has not yet been fully elucidated. Here, join the interprofessional team of Dr. Ajay Singh, Dr. Jane Davis, and Dr. Calvin Meaney as they explore an incisive review of current CKD-anemia treatment and diagnostic challenges, as well as the evidentiary base for HIF-PHI utilization in CKD-anemia that establishes context for the future of these agents. In conclusion, a practical discussion of real-world patient case scenarios will be presented, to provide learners with context of the multiple comorbidities, complexities, diagnostic challenges, and barriers to appropriate treatment of CKD-anemia.

In this podcast episode,  Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses management strategies for lower-risk myelodysplastic syndrome (MDS) with a focus on the nursing perspective. Topics includeRisk scoring and treatment algorithmsCurrent and ongoing clinical trials in the lower-risk MDS settingAdverse event profiles of current treatment optionsNursing considerations for managing a patient with lower-risk MDSPresenters:Ashley Leak Bryant, PhD, RN, OCN, FAANAssociate ProfessorSchool of NursingUNC Lineberger Comprehensive Cancer Center  University of North Carolina at Chapel HillChapel Hill, North Carolina

We'd love to hear from you (feedback@breakingbadscience.com)Look us up on social media Facebook: https://www.facebook.com/groups/385282925919540Instagram: https://www.instagram.com/breakingbadsciencepodcast/Website: http://www.breakingbadscience.com/Patreon: https://www.patreon.com/breakingbadscienceWhat causes a person to be so convinced they need to run faster, jump higher, or lift more that their own muscle tears their tendons from the bone? Combine that with something that can make a person lose impulse control and go into a rage bad enough to end like Chris Benoit and you really only have one possibility. So what are Steroids? Roids? Anabolics? Join hosts Shanti and Danny as we discuss what they are and what are their uses and misuses?ReferencesBeiner, J, et. al.; The Effect of Anabolic Steroids and Corticosteroids on Healing of Muscle Contusion Injury. American Journal of Sports Medicine. Jan-1999. 27:1 (2 - 9). Doi: https://doi.org/10.1177/03635465990270011101Salamin, O., et. al.; Erythropoietin as a Performance-Enhancing Drug: Its Mechanistic Basis, Detection, and Potential Adverse Effects. Molecular and Cellular Endocrinology. Mar-2018. 15:464 (75 - 87). Doi: https://doi.org/10.1016/j.mce.2017.01.033Wheeler, T.; Bulk Up Your Steroid Smarts. WebMD. 30-Jul-2021. https://www.webmd.com/a-to-z-guides/ss/slideshow-steroids-101Piacentino, D., et. al.; Anabolic-androgenic Steroid Use and Psychopathology in Athletes. A Systematic Review. Current Neuropharmacology. Jan-2015. 13:1 (101 - 121). Doi: https://doi.org/10.2174/1570159x13666141210222725Unger, C.; Hormone Therapy for Transgener Patients. Translational Andrology and Urology. Dec-2016. 5:6 (877 - 884). Doi: https://dx.doi.org/10.21037%2Ftau.2016.09.04Support the show (https://www.patreon.com/breakingbadscience?fan_landing=true)

FDA 批准2种治疗儿童遗传性癫痫综合征的药物NEJM 早产儿Apgar评分与新生儿死亡风险的关系Science Translational Medicine 基因治疗可逆转Danon病的代谢和多器官功能障碍司替戊醇（Stiripentol）Dravet综合征，以前称为婴儿严重肌阵挛性癫痫，是一种罕见的儿童遗传性癫痫综合征。其典型的特征是药物难治性癫痫发作，抗癫痫药物治疗是主要手段，但总体疗效有限，初始药物选择包括丙戊酸盐、苯二氮卓类药物氯巴占；一线药物治疗失败，也有选择生酮饮食疗法和神经调控技术治疗的。司替戊醇（Stiripentol，CYP450抑制剂，2018年FDA批准用于Dravet综合征的二线治疗，需与丙戊酸盐和氯巴占合用）。《STICLO-France和STICLO-Italy研究：司替戊醇治疗Dravet综合征》Drugs，2019年11月 (1)司替戊醇可以用于氯巴占和丙戊酸盐无法控制的Dravet综合征患者。佐证其疗效的最重要的两个随机对照研究分别为STICLO-France和STICLO-Italy，这两个小型的、随机对照试验，2个月的司替戊醇辅助疗法与明显优于安慰剂，两个研究数据放在一起分析，司替戊醇的缓解率是安慰剂组的10倍（70%比7%）。随后，这些短期结果被扩展为开放标签、观察性研究，当时3-21岁的参与者，长期使用该药物直至中青年，最长服药24年，疗效维持。乏力、食欲减退、体重减轻、共济失调和震颤是最常见的不良事件。结论：根据现有证据，司替戊醇作为Dravet综合征的辅助药物，疗效和安全性均较可靠。芬氟拉明（fenfluramine）2020年6月，芬氟拉明（fenfluramine），是一种安非他明的衍生物，被FDA批准用于治疗≥2岁的Dravet综合征患儿。《FAiRE DS研究：芬氟拉明剂量滴定治疗Dravet综合征的剂量滴定的3期研究》JAMA Neurology，2019年12月 (2)研究旨在评估芬氟拉明治疗司替戊醇治疗效果不佳的、Dravet综合征患者是否可以减少每月惊厥发作频率。这项双盲、安慰剂对照、平行组随机、剂量滴定的3期临床试验，纳入确诊为Dravet综合征的、2岁-18岁的、正在接受稳定剂量司替戊醇治疗的、115名儿童。他们被随机分配到芬氟拉明组和或安慰剂，经过3周的药物滴定后，进入12周的维持治疗。患儿平均年龄9.1岁，惊厥性癫痫发作平均每月25次。12周后，芬氟拉明组的患儿发作频率较安慰剂组下降54.0%；同时，芬氟拉明组54%的患者发作频率下降≥50%，而安慰剂组仅5% (P

FDA 批准2种治疗儿童遗传性癫痫综合征的药物NEJM 早产儿Apgar评分与新生儿死亡风险的关系Science Translational Medicine 基因治疗可逆转Danon病的代谢和多器官功能障碍司替戊醇（Stiripentol）Dravet综合征，以前称为婴儿严重肌阵挛性癫痫，是一种罕见的儿童遗传性癫痫综合征。其典型的特征是药物难治性癫痫发作，抗癫痫药物治疗是主要手段，但总体疗效有限，初始药物选择包括丙戊酸盐、苯二氮卓类药物氯巴占；一线药物治疗失败，也有选择生酮饮食疗法和神经调控技术治疗的。司替戊醇（Stiripentol，CYP450抑制剂，2018年FDA批准用于Dravet综合征的二线治疗，需与丙戊酸盐和氯巴占合用）。《STICLO-France和STICLO-Italy研究：司替戊醇治疗Dravet综合征》Drugs，2019年11月 (1)司替戊醇可以用于氯巴占和丙戊酸盐无法控制的Dravet综合征患者。佐证其疗效的最重要的两个随机对照研究分别为STICLO-France和STICLO-Italy，这两个小型的、随机对照试验，2个月的司替戊醇辅助疗法与明显优于安慰剂，两个研究数据放在一起分析，司替戊醇的缓解率是安慰剂组的10倍（70%比7%）。随后，这些短期结果被扩展为开放标签、观察性研究，当时3-21岁的参与者，长期使用该药物直至中青年，最长服药24年，疗效维持。乏力、食欲减退、体重减轻、共济失调和震颤是最常见的不良事件。结论：根据现有证据，司替戊醇作为Dravet综合征的辅助药物，疗效和安全性均较可靠。芬氟拉明（fenfluramine）2020年6月，芬氟拉明（fenfluramine），是一种安非他明的衍生物，被FDA批准用于治疗≥2岁的Dravet综合征患儿。《FAiRE DS研究：芬氟拉明剂量滴定治疗Dravet综合征的剂量滴定的3期研究》JAMA Neurology，2019年12月 (2)研究旨在评估芬氟拉明治疗司替戊醇治疗效果不佳的、Dravet综合征患者是否可以减少每月惊厥发作频率。这项双盲、安慰剂对照、平行组随机、剂量滴定的3期临床试验，纳入确诊为Dravet综合征的、2岁-18岁的、正在接受稳定剂量司替戊醇治疗的、115名儿童。他们被随机分配到芬氟拉明组和或安慰剂，经过3周的药物滴定后，进入12周的维持治疗。患儿平均年龄9.1岁，惊厥性癫痫发作平均每月25次。12周后，芬氟拉明组的患儿发作频率较安慰剂组下降54.0%；同时，芬氟拉明组54%的患者发作频率下降≥50%，而安慰剂组仅5% (P

On Episode 18 of the Musashi R&D Sessions Podcast, Ross and Dhiren get scientific in this week's training and sport nutrition topic – Hormones and Doping. The guys cover the purpose and effects of some of the most prominent hormones, including testosterone, cortisol, insulin and glucagon, and outline how you can impact the levels of these hormones through nutrition and exercise. We also talk about the different forms of doping, HGH and diabetes. In sports news, the guys recount several grand final wins and UFC fights from the past weekend, and Lewis Hamilton breaking the record for most wins ion Formula 1. We also recap last week's sports picks, and predict the winners of several sports matchups over the coming two weeks. Reminder: the loser between Ross and Dhiren has to eat a dry scoop of a random Musashi powder. This episode we finish with a pair of listener questions warming up and stretching, and how long to rest between working muscle groups. The guys are unable to guess the origins of a mystery famous athlete quote pitched by Hal the Intern, and Dhiren applies the philosophy of Miyamoto Musashi to the topic using the quote: “Whenever we have become preoccupied with small details, we must suddenly change into a large spirit, interchanging large with small.” Remember to comment and leave a review and we'll get in touch to send you a free Musashi T-shirt! References: Kraemer WJ & Ratamess NA. Hormonal responses and adaptations to resistance exercise and training. Sports Med 2005;35:339-361. Goto K, et al. Prior endurance exercise attenuates growth hormone response to subsequent resistance exercise. Eur J Appl Physiol 2005;94:333-338. Uchida MC, et al. Hormonal responses to different resistance exercise schemes of similar total volume. J Strength Cond Res 2009;23:2003-2008. Albright A, et al. American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc 2000;32:1345-1360. Colberg SR & Grieco CR. Exercise in the treatment and prevention of diabetes. Curr Sports Med Rep 2009;8:169-175. Tipton, et al. Timing of amino acid-carbohydrate ingestion alters anabolic response of muscle to resistance exercise. Am J Physiol Endocrinol Metab 2001;281:E197. Fortnightly Picks: State of Origin Game 1 - Wed 4th Pakistan vs Zimbabwe - Sun 1st Uriah Hall vs Anderson Silva - Sun 1st Juventus vs Barcelona - Thu 29th Dodgers vs Rays Game 6 - Wed 28th Ross: QLD, Pakistan, Hall, Barcelona, Dodgers Dhiren: NSW, Zimbabwe, Silva, Juventus, Dodgers Timestamp: 0:01:49 – Intro to topic 0:02:47 – Hormonal vs nervous system 0:04:13 – Homeostasis 0:05:25 – Testosterone 0:07:30 – Anabolic and catabolic hormones 0:09:09 – Generational testosterone levels 0:11:54 – Ratio of testosterone to cortisol 0:15:06 – Testosterone in men and women 0:17:26 – Human Growth Hormone 0:20:27 – Glands 0:22:20 – Boosting the growth hormone 0:24:16 – Roid rage 0:26:01 – Alcohol and testosterone 0:27:33 – Insulin 0:30:17 – Glucagon 0:31:11 – Diabetes 0:32:03 – Keeping insulin sensitivity high 0:32:41 – Creating an insulin spike 0:33:53 – Balancing insulin levels 0:36:44 – Cortisol 0:39:43 – Type and duration of exercise 0:42:55 – Intense exercise to boost testosterone 0:44:10 – Doping and SARMs 0:47:13 – Erythropoietin and blood doping 0:49:41 – Training at high altitudes and altitude chambers 0:51:55 – Listener questions 0:56:30 – Sports news 1:03:38 – Sports picks 1:09:15 – Mystery quote 1:10:36 – Musashi quote

Associate Professor Craig French: Erythropoietin & other inflammatory modulators. From CICM ASM PROGRAM 2019. Supported by Donate Life

The First Episode of BBP. We meet James and Charlie and discuss tall trees, doping in UFC and brain injury in contact sports. Donation link to Charlie's marathon: https://www.justgiving.com/Charles-Blake1?utm_source=Facebook&utm_medium=fundraisingpage&utm_content=Charles-Blake1&utm_campaign=pfp-share&utm_term=m3GBaexgX&fbclid=IwAR3c8r0H38dpGPzlOEO3Eq4XHdCkQFFA1ofQHlPCmGI1CPnvNUQXJIFvLKs

Master the anemia algorithm, and take a deep dive on iron deficiency, anemia of chronic kidney disease, anemia of chronic inflammation, causes of macrocytic anemia and more in this discussion with international expert, Dr. David P. Steensma, Senior Physician from Dana Farber Institute, and Associate Professor of Medicine at Harvard Medical School. Full show notes available at http://thecurbsiders.com/podcast Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Cases from Kashlak Memorial: 62 yo M with diabetes and CKD with asymptomatic Hgb 10, MCV 90, and Cr. 1.9? 72 yo F with HTN with asymptomatic Hgb of 11, MCV 85 and Cr. 0.6. 72 yo F with breast cancer in remission after lumpectomy, adjuvant chemo, and XRT treated 6 years ago presents with fatigue and some dyspnea on exertion. Hgb 9.6, MCV 102. Time Stamps 00:00 Intro 01:18 Listener feedback 04:05 Announcement: We’re looking for on air correspondents to join The Curbsiders 05:05 Picks of the week 11:12 Getting to know our guest 17:50 Case #1 Normocytic anemia 19:15 Defining anemia (WHO criteria) 21:10 Epidemiology of anemia 23:45 Normocytic anemia 25:55 Erythropoietin for diagnosis and treatment 28:22 Anemia of CKD or chronic inflammation? 31:37 Discussion of ferritin and soluble transferrin receptor 33:47 Case #1 Conclusion 35:45 Hemoglobin targets in CKD 36:53 Case #2 Microcytic anemia 37:43 Correct reticulocyte count and reticulocyte index 40:45 Deciding on dose and route for iron repletion 43:44 Does vitamin C improve iron absorption? 45:27 Case #3 Macrocytic anemia 46:54 Vitamin B12 deficiency 51:54 Medication related B12 deficiency 52:35 Myelodysplastic syndrome 55:00 Side effects of common MDS treatments 56:18 Take home points 57:35 The Curbsiders post game analysis 64:16 Outro Tags: anemia, hemoglobin, iron, supplementation, B12, vitamin, ferritin, kidney, chronic, inflammation, deficiency, oral, therapy, myelodysplastic, syndrome, assistant, care, education, doctor, family, foam, foamed, health, hospitalist, hospital, internal, internist, nurse, medicine, medical, primary, physician, resident, student

Commentary by Dr. Valentin Fuster

Interview with Claudia S. Robertson, MD, author of Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain Injury: A Randomized Clinical Trial

Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the July 02, 2014 issue

Thu, 10 Oct 2013 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/16231/ https://edoc.ub.uni-muenchen.de/16231/1/Held_Hanns-Christoph.pdf Held, Hanns-Christoph ddc:610, ddc:600, Medizinische F

Developed to save lives, its potential to give cheats an edge was soon identified. David Lindsay explores erythropoietin

Fri, 18 Jul 2008 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/9102/ https://edoc.ub.uni-muenchen.de/9102/1/Kuehnel_Sandra.pdf Kühnel, Sandra

Die kognitive Leistungsfähigkeit von Mammakarzinom-Patientinnen wurde vor Behandlungsbeginn (n=109) und vor dem letzten Zyklus neoadjuvanter Chemotherapie (n=101) mit einer neuropsychologischen Testbatterie untersucht. Bereits vor Therapiebeginn finden sich auffällig schlechte Leistungen in einem Umfang, der den in anderen Studien festgestellten kognitiven Beeinträchtigungen während oder nach einer Chemotherapie entspricht. Gegen Ende der Chemotherapie haben sich die Testleistungen der Patientinnen hochsignifikant und erheblich (Effektstärke: .75) verbessert. Es ist anzunehmen, dass ein großer Teil der Verbesserung auf Übungseffekte zurückgeht. Nach einer Korrektur der Testergebnisse für Übungseffekte zeigt sich ein gleichgroßes Ausmaß verschlechterter und verbesserter kognitiver Testleistungen gegenüber der Untersuchung vor Behandlungsbeginn: Überwiegend verschlechterten Testleistungen bei 27% stehen überwiegend verbesserte Testleistungen bei 28% der Patientinnen gegenüber. Eine vulnerable Subgruppe ist nicht erkennbar. Die wenigen Patientinnen, die auffällig viele verschlechterte Testleistungen zeigen, nahmen entweder beeinträchtigende Medikamente (n=3), oder sie hatten bei der ersten Untersuchung herausragend gute Testergebnisse erzielt (n=2), so dass ein Abfall ihrer Leistungen als Regression zur Mitte betrachtet werden kann. Dieses Ergebnismuster lässt sich schwer mit der Annahme einer Zytostatika-induzierten Schädigung in Einklang bringen. Dagegen erlaubt die Annahme einer Verursachung kognitiver Auffälligkeiten durch psychologische Faktoren, möglicherweise im Zusammenhang mit der Krankheitsbewältigung, eine sparsamere und vollständigere Erklärung der Ergebnisse unserer Studie und einiger unerklärter Beobachtungen aus anderen Untersuchungen. Selbstberichtete kognitive Probleme, Angst und Depression hängen in unserer ebenso wie in anderen Studien weder mit Testergebnissen noch mit der Veränderung von Testergebnissen zusammen, sie korrelieren aber miteinander. Entgegen den Hypothesen der Studie konnte kein neuroprotektiver Einfluss einer Begleitmedikation mit Erythropoietin festgestellt werden, und es wurden keine Zusammenhänge zwischen einer Verminderung von Aktivitäten und Verschlechterungen kognitiver Leistungsfähigkeit gefunden.

Fri, 15 Jul 2005 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/4271/ https://edoc.ub.uni-muenchen.de/4271/1/Mandel_Christina_Rikke.pdf Mandel, Christina Rikke

Die Produktion heterologer, medizinisch verwertbarer Proteine in Tieren ist heute ein Standardverfahren und viele Spezies haben sich als hierfür geeignet erwiesen. Das Huhn sollte sich besonders als Bioreaktor eignen, es verfügt zum einen über kurze Generationszeiten, und in seinem Eileiter werden täglich grosse Mengen Protein gebildet und im Ei ausgeschieden. Dennoch war es bis heute, trotz zahlreicher Anstrengungen von verschiedenen Arbeitsgruppen nicht gelungen, den Organismus eines Huhnes genetisch derart zu verändern, dass ein heterologes Protein im Eileiter gebildet, und im Ei nachweisbar ausgeschieden wird. Im Rahmen der Experimente, die in dieser Dissertation vorgestellt werden, ist es erstmals gelungen im Eileiter des Huhnes ein heterologes Protein, EPO, zu exprimieren. Es konnte nachgewiesen werden, dass das Protein aus den Zellen des Eileiters ausgeschleust wird und schliesslich im gelegten Ei in grosser Menge zu finden ist. Hierzu wurden geeignete Genkonstrukte kloniert, in vitro in primären Eileiterzellen getestet, und schliesslich per Gengun-Verfahren in vivo in den Eileiter eingebracht. Die Expression erfolgte unter der Kontrolle des viralen CMV-Promotors, das EPO-Protein war in den Eiern der positiv getesteten Tieren über Wochen nachweisbar. Aufgrund dieses Erfolges wurde versucht eine gewebespezifische Expression unter der Kontrolle des Ovalbuminpromotors zu erreichen. Es gelang ein geeignetes Promotorkonstrukt zu identifizieren und zu klonieren, sowie in vitro eine gewebespezifische Expression von ß-Galactosidase zu erreichen, eine Expression von EGFP und EPO konnte jedoch nicht sicher nachgewiesen werden. Ursächlich hierfür ist das komplexe Regulierungssystem des Ovalbuminpromotors, das durch Transfektionsverfahren empfindlich gestört wird und in vitro-Versuche beinahe unmöglich macht. Unter zu Hilfenahme eines alternativen Transfektionsverfahrens, der Virofektion gelang es jedoch unter der Kontrolle des Ovalbuminpromotors in vivo einmalig EPO-Expression in das Hühnerei nachzuweisen. Experimente, die nach Abschluss der Arbeiten an dieser Dissertation durchgeführt wurden, haben die Funktionsfähigkeit der retroviralen Konstrukte bestätigt. Insbesondere konnte unter der Kontrolle des Ovalbuminpromotors eine zellspezifische Expression von ErythropoietinErythropoietin wird aktuell auf seine biologische Aktivität untersucht, die Veröffentlichung der Ergebnisse befindet sich in Vorbereitung. erreicht werden, die Transfektion hat sich als stabil erwiesen. Das so gewonnene

Fri, 1 Jan 1999 12:00:00 +0100 https://epub.ub.uni-muenchen.de/16615/1/10_1159_000045525.pdf Bergner, A.; Lang, Susanne M.; Schiffl, Helmut ddc:610, Medizin